Long‐term response to crizotinib in a 17‐year‐old boy with treatment‐naïve ALK‐positive non‐small‐cell lung cancer

Abstract Background Lung cancer is the leading cause of cancer‐related death. NSCLC accounts for 80–90% of cases. In young patients, adenocarcinoma is the most frequent histotype and 3–7% expresses the rearrangement of ALK oncogene, sensitive to TKIs. Crizotinib is the first ALK inhibitor approved b...

Ful tanımlama

Kaydedildi:

Detaylı Bibliyografya
Asıl Yazarlar:	Giacomina Megaro, Evelina Miele, Gian Paolo Spinelli, Iside Alessi, Giada Del Baldo, Raffaele Cozza, Ida Russo, Maria Debora De Pasquale, Maria Giuseppina Cefalo, Paolo Tomà, Andrea Carai, Valentina Di Ruscio, Maria Antonietta De Ioris, Angela Mastronuzzi
Materyal Türü:	Artigo
Dil:	Inglês
Baskı/Yayın Bilgisi:	Wiley 2022-03-01
Seri Bilgileri:	Cancer Reports
Konular:	adenocarcinoma adolescence ALK crizotinib lung
Online Erişim:	https://doi.org/10.1002/cnr2.1483
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!

Long‐term response to crizotinib in a 17‐year‐old boy with treatment‐naïve ALK‐positive non‐small‐cell lung cancer

Benzer Materyaller